Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?

Sara Baldelli; Emilio Clementi; Dario Cattaneo

doi:10.1055/s-0043-122603

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2018; 51(06): 270-271
DOI: 10.1055/s-0043-122603

Letter to the Editor

Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?

Sara Baldelli

¹Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy

,

Emilio Clementi

²Clinical Pharmacology Unit, Consiglio Nazionale delle Ricerche Institute of Neuroscience, Department of Biomedical and Clinical Sciences L. Sacco University Hospital, Università degli Studi di Milano, Milan, Italy

³E. Medea Scientific Institute, Bosisio Parini, Italy

,

Dario Cattaneo

¹Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy

› Author Affiliations

Abstract

The updated AGNP Consensus Guidelines for Therapeutic Drug Monitoring (TDM) in Neuropsychopharmacology recently published in the journal have reinforced the key role of TDM to individualize psychoparmacological therapies in clinical practice. However, we believe, that these guidelines have missed the important opportunity to face with, and to provide useful information on, the emerging issue of long-acting injectable formulations of atypical antipsychotics. Specific therapeutic ranges also for these formulations should be included in the next AGNP guidelines.

Full Text

References

References
1 Hiemke C, Bergemann N. Clement et al. Consensus guidelines for therapeutic drug monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: 9-62
2 Sreeraj VS, Shivakumar V, Rao NP. et al. A critical appraisal of long acting injectable antipsychotics: Translating research to clinics. Asian J Psychiatr 2017; 28: 57-64
3 Suzuki T. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: A narrative review and critical appraisal. Expert Opin Drug Deliv. 2016; 13: 253-264
4 Biagi E, Capuzzi E, Colmegna F. et al. Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. Adv Ther 2017; 34: 1036-1048
5 Mohr P, Knytl P, Voráčková V et al. Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients. Int J Clin Pract. 2017; 71:
6 Baldelli S, Fucile S, Cattaneo D. et al. Development of a LC-MS/MS method for therapeutic drug monitoring of antidepressants and antipsychotics in human plasma. Ther Drug Monit 2011; 33: 528
7 Pozzi M, Cattaneo D, Baldelli S. et al. Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. Eur J Clin Pharmacol. 2016; 72: 285-293
8 Schoretsanitis G, Spina E, Hiemke C. et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol 2017; 10: 965-981